Respiratory
Addressing the complexity of respiratory research
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
Idiopathic pulmonary fibrosis (IPF) is a progressive and life-limiting lung disease characterised by scarring (fibrosis) of the lung tissue which primarily affects older adults. The exact cause of the disease is unknown, however, certain risk factors, such as a history of smoking, and genetic predisposition, may increase the likelihood of developing the disease.
Therapeutic Focus - Pushing Boundaries in Idiopathic Pulmonary Fibrosis Clinical Research
With more than 170 early stage IPF clinical programs, IPF is one of the most dynamic rare diseases spaces for development.
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
The landscape of IPF research is evolving and early-stage biopharmaceutical teams need a new roadmap to success. We offer strategies to meet the challenges to develop new treatments.
Pandemic respiratory vaccine clinical trials: A departure from business as usual
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.